GSK plc (LON:GSK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1,805.00
-21.00 (-1.15%)
At close: Dec 5, 2025
33.21%
Market Cap72.45B
Revenue (ttm)32.17B
Net Income (ttm)5.49B
Shares Out4.01B
EPS (ttm)1.33
PE Ratio13.58
Forward PE10.08
Dividend0.61 (3.38%)
Ex-Dividend DateNov 13, 2025
Volume4,275,805
Average Volume8,560,235
Open1,826.50
Previous Close1,826.00
Day's Range1,796.00 - 1,833.50
52-Week Range1,242.50 - 1,853.50
Beta0.23
RSI57.57
Earnings DateFeb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange London Stock Exchange
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial Statements

News

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...

1 day ago - Reuters

Is GSK PLC Gaining or Losing Market Support?

GSK PLC's (NYSE: GSK) short interest as a percent of float has fallen 12.68% since its last report. According to exchange reported data, there are now 12.55 million shares sold short , which is 0.62%...

1 day ago - Benzinga

AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report

The U.K. government is bringing together senior pharmaceutical executives to help chart a new direction for the country's drug-pricing system . Whitehall officials will invite reps from AstraZeneca Pl...

3 days ago - Benzinga

FENI, BTI, GSK, MNDY: ETF Inflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...

4 days ago - Nasdaq

BREAKING: Trump strikes major deal with UK on drug pricing

FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.'

5 days ago - Fox Business

Market Outlook: High-conviction stock picks from a seasoned portfolio manager

Top stock picks from Sartorial Wealth’s Shiraz Ahmed using momentum and risk-adjusted analysis, including Royal Bank, Franco-Nevada, Alibaba and GSK.

8 days ago - BNN Bloomberg

AnaptysBio Buckles After Trading Legal Barbs With Pharma Giant GSK

AnaptysBio stock buckled Friday after the biotech company and GSK filed competing lawsuits against one another over a licensing deal.

15 days ago - Investor's Business Daily

Why GSK (GSK) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

15 days ago - Nasdaq

AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement

AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement

15 days ago - GuruFocus

AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK

AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK

15 days ago - GuruFocus

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a par...

15 days ago - Reuters

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE: GSK) subsidiary, Tesaro Inc ., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court. ANAB is encountering selling pressure. Get the scoop he...

15 days ago - Benzinga

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.

15 days ago - Benzinga

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.

15 days ago - WSJ

GSK Faces Legal Challenge Over Alleged Interference with AnaptysBio Collaboration

GSK Faces Legal Challenge Over Alleged Interference with AnaptysBio Collaboration

15 days ago - GuruFocus

TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement

(RTTNews) - GSK plc.'s (GSK) subsidiary TESARO Inc. has commenced litigation against AnaptysBio Inc. (ANAB), contending that AnaptysBio has materially violated the terms of their licensing agreement r...

15 days ago - Nasdaq

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a ...

15 days ago - GlobeNewsWire

GSK's Tesaro Sues AnaptysBio Over Jemperli License Dispute

(RTTNews) - GSK plc (GSK), a biopharmaceutical company's subsidiary Tesaro, Inc. (TSRO), on Friday announced that it has filed litigation in the Delaware Chancery Court against AnaptysBio, Inc. (ANAB)...

15 days ago - Nasdaq

GSK (GSK) Pursues Legal Action Against AnaptysBio Over License Dispute

GSK (GSK) Pursues Legal Action Against AnaptysBio Over License Dispute

15 days ago - GuruFocus

GSK (GSK) Partners with LTZ for Innovative Cancer Treatments

GSK (GSK) Partners with LTZ for Innovative Cancer Treatments

16 days ago - GuruFocus

GSK inks deal with LTZ Therapeutics to develop hematologic cancer therapies

GSK partners with LTZ Therapeutics to develop novel myeloid cell engager treatments for cancer using innovative immuno-oncology technology. Read more here.

16 days ago - Seeking Alpha

GSK (GSK): CDC Updates Vaccination and Autism Information

GSK (GSK): CDC Updates Vaccination and Autism Information

16 days ago - GuruFocus